Navigation Links
China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference
Date:11/15/2010

China Biologic Products to Present at Brean Murray, Carret 2010 China Growth... -- TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

China Biologic Products to Present at Brean Murray, Carret 2010 China Growth Conference

 

TAI'AN, China, Nov. 15, 2010 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that the Company's management will present at the upcoming Brean Murray, Carret & Co. 2010 China Growth Conference. Date:

November 17, 2010 Time:

09:20 a.m. ESTPresenter:

Ming Yin, Vice President - Finance Location:

Track IIThe Millennium Broadway Hotel145 West 44th StreetNew York, New York 10036The Brean Murray, Carret & Co. 2010 China Growth Conference is a two-day conference (November 17-18, 2010) that consists of 25-minute presentation slots followed by 10-minutes of open floor Q&A sessions with institutional investors. Senior management of presenting companies, industry experts, and institutional investors will receive a unique and comprehensive view of China from a global perspective. China Biologic's management will be available for 1x1 meetings before and after the Company's presentation.

About China Biologic Products, Inc.China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biological Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical company in China. The Company is a fully integrated biological products company with plasma collection, production and manufacturing, research and development and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China.

Company Contact:Mr. Ming YinVice President - FinanceChina Biologic Products, Inc.Tel: +86-851-3605846Email: IR@chinabiologic.comwww.chinabiologic.com Investor Relations Contact:Mr. Crocker Coulson, President CCG Investor RelationsPhone: +1 (646) 213-1915Email: crocker.coulson@ccgir.comwww.ccgirasia.com
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics Appoints New Chief Operating Officer
2. China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results
3. China-Biotics to Report Fiscal Year 2011 Second Quarter Financial Results on November 9
4. Verenium Announces Regulatory Approval for Purifine® PLC in China
5. China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
6. Reportlinker Adds Industrial Biotechnology China News 1009
7. According to Opurity, Feds Put U.S. Consumers at Risk: PTO Bureaucrats Refuse to Approve Vitamin Companys China-Free Trademark
8. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
9. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
10. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
11. China-Biotics Hosted its First Investor Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
Breaking Biology Technology:
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):